Status:
COMPLETED
A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor
Lead Sponsor:
Ziv Hospital
Conditions:
Liver Fibrosis
Eligibility:
All Genders
18-90 years
Brief Summary
Soluble secreted proteins that are expressed uniquely in specific organs and whose formation of secretion is regulated by disease states are excellent markers for the disease. This is because the dise...
Eligibility Criteria
Inclusion
- Signed informed consent.
- Patient candidate to bariatric surgery.
Exclusion
- Liver biopsy during the last 12 months.
- The surgeon consider liver biopsy as a special dander in a specific patient.
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT00941902
Start Date
May 1 2009
End Date
February 1 2011
Last Update
May 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ZIV Medical Center
Safed, Israel, 13110